Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

November 13, 2019 Capital Markets and Public M&A

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

The subscription price was determined to SEK 16 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates. 
Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Stephanie Stiernstedt.

 

Related

Vinge advises Pricer in connection with Vusion’s public takeover offer

On 17 November 2026, VusionGroup S.A., a French public limited company listed on Euronext Paris, announced a recommended public takeover offer to the shareholders of Pricer Aktiebolag (publ) to acquire all shares in Pricer for a consideration of SEK 6.00 per share. The offer values all shares in Pricer at approximately SEK 980.4 million.
November 20, 2026

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026